**Core Concept**
Type I hepatorenal syndrome (HRS) is a rapidly progressive form of kidney dysfunction in patients with cirrhosis, characterized by a significant decrease in renal function and a high mortality rate. The underlying pathophysiology involves a complex interplay of vasoconstriction, endothelial dysfunction, and systemic circulatory changes.

**Why the Correct Answer is Right**
The treatment of choice for Type I HRS is transjugular intrahepatic portosystemic shunt (TIPS) placement. TIPS works by reducing portal pressure and promoting renal perfusion by creating a shunt between the hepatic vein and a branch of the portal vein. This leads to an increase in effective circulating volume, which helps to improve renal function. The use of vasoconstrictors such as midodrine and octreotide is often used in conjunction with TIPS to further enhance its effects.

**Why Each Wrong Option is Incorrect**
**Option A:** Liver transplantation is a definitive treatment for HRS, but it is not the most effective treatment for Type I HRS, which requires immediate intervention to stabilize the patient.
**Option B:** Vasopressin is not an effective treatment for Type I HRS, as it can actually worsen renal function by causing further vasoconstriction.
**Option C:** MELD (Model for End-Stage Liver Disease) scoring system is used to assess the severity of liver disease, but it is not a treatment for HRS.

**Clinical Pearl / High-Yield Fact**
TIPS placement is a life-saving intervention for patients with Type I HRS, and it should be considered in all patients who present with this condition.

**Correct Answer: C. MELD scoring system is used to assess the severity of liver disease, but it is not a treatment for HRS.**